Navigation Links
Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
Date:11/21/2013

its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as "anticipates," "estimates," "believes," "intends," "potential," or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines, obtaining regulatory approvals and manufacturing vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the US Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program.  These and other risk factors are described from time to time in filings with
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
2. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
3. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
4. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
5. FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
6. Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
11. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , 27. März 2015  Peter Walter ... Biomedical Science für seine bahnbrechende Arbeit ausgewählt, ... Zellkompartimenten transportiert werden, sowie für die Entschlüsselung ... Reaktion auf Stress nutzen, der mit der ... ist Professor für Biochemie an der University ...
(Date:3/27/2015)... , March 27, 2015   SurePure, ... liquid photopurification, announced today that the Company has ... the continued trading of SurePure ("SURP") securities on ... marketplace for entrepreneurial and development stage companies. ... introduced standards and eligibility requirements designed to improve ...
(Date:3/27/2015)... , March 27, 2015 Working in ... Hospital in London , Richmond Pharmacology is ... global Phase 3 study for an investigational RNAi therapeutic being ... disease affecting the nerves and heart. Read ... Based at St Georges University of ...
(Date:3/27/2015)... March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... months ended December 31, 2014.  The ... ($0.05) per share, for the three months ended December ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6
... CLEVELAND, Ohio , May 24, 2010 Simbionix ... medical professionals and the healthcare industry, is launching,two new hands-on training systems- ... revealed for the first time at,the AUA annual meeting in San ... , ...
... ... Key Data to Drive Real-time Interactive Life Science Research , ... (PRWEB) May 24, 2010 -- Genedata, a ... announced Genedata Expressionist 6 , which is a major new release of the ...
... , May 24 Dynamic, thorough, and robustly ... our newest Scientific Content Consultant, Philippe Vitat, who brings with ... Mr. Vitat has worked as a certified medical writer and ... of the World" in medical education by the International Biographical ...
Cached Biology Technology:Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 2Simbionix to Reveal Two new Products at the Upcoming American Urology Association (AUA) Annual Meeting 3Genedata Expressionist 6 with New Refiner MS Capabilities Debuts at 58th ASMS Conference on Mass Spectrometry 2Genedata Expressionist 6 with New Refiner MS Capabilities Debuts at 58th ASMS Conference on Mass Spectrometry 3Genedata Expressionist 6 with New Refiner MS Capabilities Debuts at 58th ASMS Conference on Mass Spectrometry 4Highly Regarded Medical Writer Joins Avant Healthcare Marketing Team 2
(Date:3/12/2015)... The mascots of the Atlantic Coast Conference ... Wake Forest Baptist Medical Center. They stopped by as ... Men,s Basketball Tournament. Young patients enjoyed bonding with their ... autographs. Brenner Children,s Hospital is the pediatric ... children,s hospital in northwest North Carolina ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
(Date:3/10/2015)... BOULDER, Colo. , March 10, 2015 ... Space Flight "Personalized Medicine in Human ... Ph.D. and Thomas J. Goodwin , Ph.D. was ... articles of the past two years. Specifically, ... three most downloaded scientific papers published in 2013 and ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2
... (HSCI) researchers have a new model for how the kidney ... of evidence that mature cells are far more plastic than ... kidney cells dedifferentiate into more primordial versions of themselves, and ... damaged tissue. This finding conflicts with a previously held theory ...
... sugar intake is not directly associated with nonalcoholic fatty ... Gastroenterology , the official journal of the American Gastroenterological ... serious form of liver disease. Researchers conducted a ... compare the effects of high intakes of two types ...
... that low-frequency repetitive transcranial magnetic stimulation (rTMS), ... antiepileptic effects, the mechanism remains unclear. Prof. ... Hospital of North Sichuan Medical College, China ... magnetic simulation on changes in several nonlinear ...
Cached Biology News:A new model for organ repair 2Sugar intake is not directly related to liver disease 2
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Jak3 Antibody Ship: Hot Store: -20 C...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: